The estimated Net Worth of Mark A. Kronenfeld is at least $943 Thousand dollars as of 8 June 2023. Mark Kronenfeld owns over 15,000 units of Pacira BioSciences Inc stock worth over $427,661 and over the last 11 years he sold PCRX stock worth over $84,510. In addition, he makes $430,946 as Independent Director at Pacira BioSciences Inc.
Mark has made over 8 trades of the Pacira BioSciences Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he exercised 15,000 units of PCRX stock worth $448,500 on 8 June 2023.
The largest trade he's ever made was exercising 15,000 units of Pacira BioSciences Inc stock on 8 June 2023 worth over $448,500. On average, Mark trades about 1,064 units every 169 days since 2013. As of 8 June 2023 he still owns at least 32,897 units of Pacira BioSciences Inc stock.
You can see the complete history of Mark Kronenfeld stock trades at the bottom of the page.
Dr. Mark A. Kronenfeld M.D. serves as Independent Director of the Company. Dr. Kronenfeld has been the Vice Chairman of Anesthesiology at Maimonides Medical Center, a large tertiary care academic medical center in New York City, since March 2009, and has served as Medical Director of Perioperative Services for Maimonides Medical Center since January 2011. Dr. Kronenfeld is a Managing Partner of Anesthesia Associates of Boro Park, a private medical practice, and a Managing Partner of Strategic Medical Management Partners. In 2001, Dr. Kronenfeld founded Ridgemark Capital Management ("Ridgemark"), a healthcare-focused hedge fund that invested in public and private healthcare and biomedical companies. He served as the Managing Partner and Portfolio Manager of Ridgemark from April 2001 to December 2008. Dr. Kronenfeld has founded and/or managed various consulting and investment companies focused on healthcare and medical technologies and has served on and chaired multiple leadership committees for various hospitals and medical centers. Previously, Dr. Kronenfeld taught and practiced adult and pediatric cardiac anesthesia at New York University ("NYU") and was Chief of Cardiac Anesthesiology at Hackensack University Medical Center and President of GMS Anesthesia Associates, a private medical practice. Dr. Kronenfeld received his B.A. in Biology from SUNY Buffalo, his M.D. degree and completed his residency in Anesthesiology at the University of California, San Diego School of Medicine, and completed a fellowship in Cardiothoracic Anesthesiology at New York University Medical Center. While an Assistant Professor and Attending Cardiac Anesthesiologist at NYU, Dr. Kronenfeld received and completed a Kellogg-sponsored Fellowship in Heath Care Management for Future Leaders in Health Care at NYU's Graduate School of Management.
As the Independent Director of Pacira BioSciences Inc, the total compensation of Mark Kronenfeld at Pacira BioSciences Inc is $430,946. There are 16 executives at Pacira BioSciences Inc getting paid more, with David Stack having the highest compensation of $5,806,430.
Mark Kronenfeld is 65, he's been the Independent Director of Pacira BioSciences Inc since 2013. There are 3 older and 22 younger executives at Pacira BioSciences Inc. The oldest executive at Pacira BioSciences Inc is Gary Pace, 72, who is the Independent Director.
Mark's mailing address filed with the SEC is C/O PACIRA BIOSCIENCES, INC., 5401 WEST KENNEDY BOULEVARD, SUITE 890, TAMPA, FL, 33609.
Over the last 14 years, insiders at Pacira BioSciences Inc have traded over $321,391,130 worth of Pacira BioSciences Inc stock and bought 2,075,444 units worth $15,133,188 . The most active insiders traders include Advisors Llc Orbi Med Capit..., Carl L Gordon, and Andreas Wicki. On average, Pacira BioSciences Inc executives and independent directors trade stock every 13 days with the average trade being worth of $491,036. The most recent stock trade was executed by Marcelo Bigal on 16 August 2024, trading 1,512 units of PCRX stock currently worth $20,034.
pacira pharmaceuticals, inc. (nasdaq: pcrx) is an emerging specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. the company's current emphasis is the development of non-opioid products for postsurgical pain control, and its lead product, exparel® (bupivacaine liposome injectable suspension), was commercially launched in the united states in april 2012. exparel and two other products have utilized the pacira proprietary product delivery technology depofoam®, a unique platform that encapsulates drugs without altering their molecular structure and then releases them over a desired period of time.
Pacira BioSciences Inc executives and other stock owners filed with the SEC include: